Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study

Fig. 2

Cumulative risk of incident AF for the paired study cohorts treated with SGTL2i versus DPP4i (A), SGLT2i versus GLP-1RA (B), and GLP-1RA versus DPP4i (C) after PSM. There was a clear separation of event curves for new-onset AF between the paired SGLT2i and DPP4i group and the paired SGLT2i and GLP-1RA group after PSM adjustment. SGLT2i treatment was associated with a lower risk of new-onset AF in participants with type 2 diabetes compared with DPP4i or GLP-1RA treatment after PSM. Conversely, there was no difference in the risk of incident AF between the GLP-1RA and DPP4i treatment

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840